HOPKINTON, Mass., Feb. 19 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, today announced the formation of a scientific advisory board to guide its efforts in automated sample preparation for next generation and third generation sequencing platforms. Caliper worked closely with leading genome centers to develop the LabChip® XT, which was announced today, and is now expanding its efforts to develop additional solutions for next generation sequencing workflows.
"Although tremendous advances have been made in next and third generation sequencing instrumentation and informatics, there remains an unmet need for high quality sample preparation techniques," said Kevin Hrusovsky, President and CEO, Caliper Life Sciences. "We are working with the world renowned members of our Sequencing Advisory Board to identify opportunities that improve sequencing workflows while leveraging Caliper's extensive microfluidics IP estate. We continue to assess strategic opportunities to directly commercialize products and to out-license our microfluidic technology to collaborators."
Caliper's Sequencing Scientific Advisory Board (SAB) includes the following experts:
Dr. Michael Quail, Wellcome Trust Sanger Institute
Dr. Vincent Magrini, Washington University Genome Sequencing Center
Dr. Patrick Cahill, The Broad Institute of MIT and Harvard
Dr. Christopher Detter, U.S. Department of Energy - Joint Genome Institute
Dr. Jan Fang Cheng, U.S. Department of Energy - Joint Genome Institute
Mr. John Gill, J. Craig Venter Institute
Mrs. Karen Beeson, J. Craig Venter Institute
Several Caliper solutions for next generation sequencing will be presented next week at Advances in Biology and Genomic Technologies (AGBT) in Marco Island, Florida. Caliper Life Sciences will introduce an Early Access Innovators program for the LabChip XT and will showcase automation and high throughput separation solutions, as well as the fractionation instrument. For additional information, please visit http://www.caliperLS.com
About Caliper Life Sciences
Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit www.caliperLS.com.
Caliper and LabChip are registered trademarks of Caliper Life Sciences, Inc.
SOURCE Caliper Life Sciences, Inc.
Advertisement
"Although tremendous advances have been made in next and third generation sequencing instrumentation and informatics, there remains an unmet need for high quality sample preparation techniques," said Kevin Hrusovsky, President and CEO, Caliper Life Sciences. "We are working with the world renowned members of our Sequencing Advisory Board to identify opportunities that improve sequencing workflows while leveraging Caliper's extensive microfluidics IP estate. We continue to assess strategic opportunities to directly commercialize products and to out-license our microfluidic technology to collaborators."
Advertisement
Caliper's Sequencing Scientific Advisory Board (SAB) includes the following experts:
Dr. Michael Quail, Wellcome Trust Sanger Institute
Dr. Vincent Magrini, Washington University Genome Sequencing Center
Dr. Patrick Cahill, The Broad Institute of MIT and Harvard
Dr. Christopher Detter, U.S. Department of Energy - Joint Genome Institute
Dr. Jan Fang Cheng, U.S. Department of Energy - Joint Genome Institute
Mr. John Gill, J. Craig Venter Institute
Mrs. Karen Beeson, J. Craig Venter Institute
Several Caliper solutions for next generation sequencing will be presented next week at Advances in Biology and Genomic Technologies (AGBT) in Marco Island, Florida. Caliper Life Sciences will introduce an Early Access Innovators program for the LabChip XT and will showcase automation and high throughput separation solutions, as well as the fractionation instrument. For additional information, please visit http://www.caliperLS.com
About Caliper Life Sciences
Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit www.caliperLS.com.
Caliper and LabChip are registered trademarks of Caliper Life Sciences, Inc.
SOURCE Caliper Life Sciences, Inc.
